Trial Profile
An open label, multicenter, randomized, parallel controlled study to compare the efficacy and safety profile of chemo-radiotherapy with concomitant HMPL-002 use compared to standard chemo-radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs HMPL 002 (Primary) ; Antineoplastics
- Indications Cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
- 23 Feb 2009 New trial record.
- 08 Feb 2009 Interim results data have been reported in a Chi-Med media release.